

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-77. canceled.

78. (Currently amended) A method of treating an immune disease in a subject, comprising parenterally administering to a subject that has been diagnosed with an immune disease a therapeutically effective amount of a sterile injectable composition comprising an antibody or antibody fragment specific to a marker associated with a B-cell a B-cell antibody or fragment thereof in a pharmaceutically acceptable injection vehicle.

79. (Previously presented) A method according to claim 78, wherein the subject has been diagnosed with immune thrombocytopenic purpura.

80. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is a Fv, single chain antibody, Fab, Fab', or F(ab')<sub>2</sub> fragment.

81. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is an intact antibody.

82. (Previously presented) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a therapeutic agent.

83. (Currently amended) A method according to claim 82, wherein the therapeutic agent is a cytotoxic agent.

84. (Previously presented) A method according to claim 83, wherein the cytotoxic agent is a therapeutic radioisotope.

85. (Currently amended) A method according to claim 82, wherein the therapeutic agent is a drug.

86. (Currently amended) A method according to claim 82, wherein the therapeutic agent is a toxin.

87-92. Canceled.

93. (Currently amended) A method of treating an immune disease in a subject, comprising parenterally administering to a subject that has been diagnosed with an immune disease a therapeutically effective amount of a sterile injectable composition comprising an antibody specific to a marker associated with a B-cell a B-cell antibody or fragment thereof in a pharmaceutically acceptable injection vehicle.

acceptable injection vehicle, wherein the antibody or fragment thereof is an antibody having multiple epitope or multiple antigen specificity.

94. (New) A method according to claim 78, wherein the antibody or antibody fragment is a human monoclonal antibody.

95. (New) A method according to claim 78, wherein the antibody or antibody fragment is a mouse/human chimeric monoclonal antibody.

96. (New) A method according to claim 78, wherein the antibody or antibody fragment is a genetically engineered antibody.

97. (New) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a therapeutic agent.

98. (New) A method according to claim 97, wherein the antibody or antibody fragment is conjugated to a cytotoxic agent.

99. (New) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a drug.

100. (New) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a radioisotope.

101. (New) A method according to claim 78, wherein the antibody or antibody fragment is conjugated to a cytokine.